Pharmacokinetic studies of 13-cis retinoic acid (13cRA) and all-trans retinoic acid (ATRA), the 2 most commonly used retinoids, have suggested significant differences in the disposition of these compounds despite their structural similarity. In vivo treatment with 13cRA has been associated with 20-3
Pharmacokinetics of parenteral 13-cis-retinoic acid formulations in rats
โ Scribed by H. J. Guchelaar; S. Wouda; G. J. J. Beukeveld; N. H. Mulder; J. W. Oosterhuis
- Publisher
- John Wiley and Sons
- Year
- 1992
- Tongue
- English
- Weight
- 407 KB
- Volume
- 81
- Category
- Article
- ISSN
- 0022-3549
No coin nor oath required. For personal study only.
โฆ Synopsis
The pharmacokinetics of three 13-cis-retinoic acid formulations were studied after intraperitoneal (ip) administration to rats. Rats were given ip injections of 2.5 mg of 13-cis-retinoic acid per 360 g of body weight; the drug was administered as an alkaline solution, suspended in corn oil, or as a mixture with polysorbate 80. The alkaline solution was also given intravenously (iv) via the tail vein as a control. The mean elimination rate constant, calculated from data from iv administration, was 0.72 +/- 0.088 h-1 (r = 0.988). The peak concentration in plasma and the time to reach this maximum were 14 mg/L and 0.5 h, 22 mg/L and 2 h, and 10 mg/L and 1 h for the drug administered as an alkaline solution, suspended in corn oil, and as a mixture with polysorbate 80, respectively. The areas under the concentration-time curve (concentration in plasma versus time) were 34.9 +/- 8.78 mg.h/L for the iv dose and 34.1 +/- 9.97, 62.4 +/- 32.3, and 25.9 +/- 12.0 mg.h/L for the ip doses of alkaline solution, suspension in oil, and mixture with polysorbate 80, respectively. Because of the rapid increase of concentration in plasma, which is identical to that of the iv profile, and the ease of its handling and preparation, the ip administered alkaline solution is the preferable formulation.
๐ SIMILAR VOLUMES
Animal studies indicate that 13-cis-retinoic acid (CRA) inhibits bladder tumor growth and is effective in treating patients with serious dermatologic disorders. A trial of CRA in patients at high risk for recurrent Ta, T l tumors was initiated at an experimental dose of 0.5 mg/kg/d in three divided